Biomarker Discovery

BiomarkerIdentificatoin-detection.PNG

Biomarker Contract Research Programs

Diseases are frequently caused by the variation of multiple protein levels or activities in the human body. Those proteins represent primary targets for drug development and are potential biomarkers indicative of increased risk of disease development and progression. To develop biomarkers allowing the early detection of a disease it is essential to understand the underlying molecular disease mechanisms generating those markers. Recent improvements of marker detection technologies in vivo, in organs/tissues, and in relevant, physiological cellular models greatly improve the understanding of key biological functions such as cell signaling pathway and facilitate the identification of potential disease markers. Our Biomarker Contract Research Programs utilize diverse, complementary technologies and biology models for accurate biomarker identification and quantification. Our programs have the potential to i) provide a clearer understanding of disease molecular mechanisms and identify more relevant protein markers responsible for disease development and progression, ii) detect the disease occurrence at an earlier development stage thus improving diagnostic and therapy treatment efficacy, iii) identify and validate drug efficacy and safety biomarkers to maximize drug patient selection and reduce drug safety attrition in clinical trials.

We utilize a wide range of techniques and models to conduct biomarker discovery and analysis studies in cell based assays, animal disease models and in tissues: 

Gene fusion and translocation, gene expression and FISH approaches are DNA and RNA based techniques that provide important information on genetic background and on the way specific protein markers are up and down regulated. Functional Signaling Pathway Analysis measures the activity of specific kinases in cells and is essential to study oncology/inflammation efficacy markers and to uncover/analyze safety biomarkers in general. The titration of specific disease relevant cellular metabolic intermediates is a great complement of signaling pathway studies and helps developing a better understanding of disease mechanisms. Immuno-Fluorescence (IF) and Multispectral Tissue Immuno-HistoChemistry (IHC) in single tissue slides or in Tissue Micro Arrays (TMAs) measure very specific protein marker expression using our state of the art Vectra™ tissue imaging technology platform. Measuring protein biomarkers in multiplex, from a same tissue slide preparation generates content-rich information from human tissue samples often available in very limited supply. Other techniques measuring levels of protein markers in biological samples are available and include Luminex X-MAP, protein/antibody arrays, ELISA, Western Blots.

Our biomarker studies are conducted at preclinical stage, using cell based, animal models and human samples collected from clinical trials or from human tissue repositories. Our multidisciplinary team of scientists will work closely with you to design the biomarker discovery/analysis program that best fits you research goals and objectives.